Dataset Information

Distinct molecular profiles of skull bone marrow in health and neurological disorders.

ABSTRACT: The bone marrow in the skull is important for shaping immune responses in the brain and meninges, but its molecular makeup among bones and relevance in human diseases remain unclear. Here, we show that the mouse skull has the most distinct transcriptomic profile compared with other bones in states of health and injury, characterized by a late-stage neutrophil phenotype. In humans, proteome analysis reveals that the skull marrow is the most distinct, with differentially expressed neutrophil-related pathways and a unique synaptic protein signature. 3D imaging demonstrates the structural and cellular details of human skull-meninges connections (SMCs) compared with veins. Last, using translocator protein positron emission tomography (TSPO-PET) imaging, we show that the skull bone marrow reflects inflammatory brain responses with a disease-specific spatial distribution in patients with various neurological disorders. The unique molecular profile and anatomical and functional connections of the skull show its potential as a site for diagnosing, monitoring, and treating brain diseases.

SUBMITTER: Kolabas ZI

PROVIDER: S-EPMC10443631 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Distinct molecular profiles of skull bone marrow in health and neurological disorders.

Kolabas Zeynep Ilgin ZI Kuemmerle Louis B LB Perneczky Robert R Förstera Benjamin B Ulukaya Selin S Ali Mayar M Kapoor Saketh S Bartos Laura M LM Büttner Maren M Caliskan Ozum Sehnaz OS Rong Zhouyi Z Mai Hongcheng H Höher Luciano L Jeridi Denise D Molbay Muge M Khalin Igor I Deligiannis Ioannis K IK Negwer Moritz M Roberts Kenny K Simats Alba A Carofiglio Olga O Todorov Mihail I MI Horvath Izabela I Ozturk Furkan F Hummel Selina S Biechele Gloria G Zatcepin Artem A Unterrainer Marcus M Gnörich Johannes J Roodselaar Jay J Shrouder Joshua J Khosravani Pardis P Tast Benjamin B Richter Lisa L Díaz-Marugán Laura L Kaltenecker Doris D Lux Laurin L Chen Ying Y Zhao Shan S Rauchmann Boris-Stephan BS Sterr Michael M Kunze Ines I Stanic Karen K Kan Vanessa W Y VWY Besson-Girard Simon S Katzdobler Sabrina S Palleis Carla C Schädler Julia J Paetzold Johannes C JC Liebscher Sabine S Hauser Anja E AE Gokce Ozgun O Lickert Heiko H Steinke Hanno H Benakis Corinne C Braun Christian C Martinez-Jimenez Celia P CP Buerger Katharina K Albert Nathalie L NL Höglinger Günter G Levin Johannes J Haass Christian C Kopczak Anna A Dichgans Martin M Havla Joachim J Kümpfel Tania T Kerschensteiner Martin M Schifferer Martina M Simons Mikael M Liesz Arthur A Krahmer Natalie N Bayraktar Omer A OA Franzmeier Nicolai N Plesnila Nikolaus N Erener Suheda S Puelles Victor G VG Delbridge Claire C Bhatia Harsharan Singh HS Hellal Farida F Elsner Markus M Bechmann Ingo I Ondruschka Benjamin B Brendel Matthias M Theis Fabian J FJ Erturk Ali A

Cell 20230809 17

The bone marrow in the skull is important for shaping immune responses in the brain and meninges, but its molecular makeup among bones and relevance in human diseases remain unclear. Here, we show that the mouse skull has the most distinct transcriptomic profile compared with other bones in states of health and injury, characterized by a late-stage neutrophil phenotype. In humans, proteome analysis reveals that the skull marrow is the most distinct, with differentially expressed neutrophil-relat ...[more]

PMID: 37562402

Similar Datasets

Project description:Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) characterized by demyelination and axonal loss. Demyelinating lesions are associated with infiltrating T lymphocytes, bone marrow-derived macrophages (BMDM), and activated resident microglia. Tissue damage is thought to be mediated by T cell produced cytokines and chemokines, which activate microglia and/or BMDM to both strip myelin and produce toxic factors, ultimately damaging axons and promoting disability. However, the relative contributions of BMDM and microglia to demyelinating pathology are unclear, as their identification in MS tissue is difficult due to similar morphology and indistinguishable surface markers when activated. The CD4 T cell-induced autoimmune murine model of MS, experimental autoimmune encephalitis (EAE), in which BMDM are essential for demyelination, has revealed pathogenic and repair-promoting phenotypes associated with BMDM and microglia, respectively. Using a murine model of demyelination induced by a gliatropic coronavirus, in which BMDM are redundant for demyelination, we herein characterize gene expression profiles of BMDM versus microglia associated with demyelination. While gene expression in CNS infiltrating BMDM was upregulated early following infection and subsequently sustained, microglia expressed a more dynamic gene profile with extensive mRNA upregulation coinciding with peak demyelination after viral control. This delayed microglia response comprised a highly pro-inflammatory and phagocytic profile. Furthermore, while BMDM exhibited a mixed phenotype of M1 and M2 markers, microglia repressed the vast majority of M2-markers. Overall, these data support a pro-inflammatory and pathogenic role of microglia temporally remote from viral control, whereas BMDM retained their gene expression profile independent of the changing environment. As demyelination is caused by multifactorial insults, our results highlight the plasticity of microglia in responding to distinct inflammatory settings, which may be relevant for MS pathogenesis.

Project description:Cannabis has a long history of anecdotal medicinal use and limited licensed medicinal use. Until recently, alleged clinical effects from anecdotal reports and the use of licensed cannabinoid medicines are most likely mediated by tetrahydrocannabinol by virtue of: 1) this cannabinoid being present in the most significant quantities in these preparations; and b) the proportion:potency relationship between tetrahydrocannabinol and other plant cannabinoids derived from cannabis. However, there has recently been considerable interest in the therapeutic potential for the plant cannabinoid, cannabidiol (CBD), in neurological disorders but the current evidence suggests that CBD does not directly interact with the endocannabinoid system except in vitro at supraphysiological concentrations. Thus, as further evidence for CBD's beneficial effects in neurological disease emerges, there remains an urgent need to establish the molecular targets through which it exerts its therapeutic effects. Here, we conducted a systematic search of the extant literature for original articles describing the molecular pharmacology of CBD. We critically appraised the results for the validity of the molecular targets proposed. Thereafter, we considered whether the molecular targets of CBD identified hold therapeutic potential in relevant neurological diseases. The molecular targets identified include numerous classical ion channels, receptors, transporters, and enzymes. Some CBD effects at these targets in in vitro assays only manifest at high concentrations, which may be difficult to achieve in vivo, particularly given CBD's relatively poor bioavailability. Moreover, several targets were asserted through experimental designs that demonstrate only correlation with a given target rather than a causal proof. When the molecular targets of CBD that were physiologically plausible were considered for their potential for exploitation in neurological therapeutics, the results were variable. In some cases, the targets identified had little or no established link to the diseases considered. In others, molecular targets of CBD were entirely consistent with those already actively exploited in relevant, clinically used, neurological treatments. Finally, CBD was found to act upon a number of targets that are linked to neurological therapeutics but that its actions were not consistent withmodulation of such targets that would derive a therapeutically beneficial outcome. Overall, we find that while >65 discrete molecular targets have been reported in the literature for CBD, a relatively limited number represent plausible targets for the drug's action in neurological disorders when judged by the criteria we set. We conclude that CBD is very unlikely to exert effects in neurological diseases through modulation of the endocannabinoid system. Moreover, a number of other molecular targets of CBD reported in the literature are unlikely to be of relevance owing to effects only being observed at supraphysiological concentrations. Of interest and after excluding unlikely and implausible targets, the remaining molecular targets of CBD with plausible evidence for involvement in therapeutic effects in neurological disorders (e.g., voltage-dependent anion channel 1, G protein-coupled receptor 55, CaV3.x, etc.) are associated with either the regulation of, or responses to changes in, intracellular calcium levels. While no causal proof yet exists for CBD's effects at these targets, they represent the most probable for such investigations and should be prioritized in further studies of CBD's therapeutic mechanism of action.

Dataset Information

Distinct molecular profiles of skull bone marrow in health and neurological disorders.

Publications

Distinct molecular profiles of skull bone marrow in health and neurological disorders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets